Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.
Aim(s): The current study was to evaluate the role of serum CA19-9 levels as a prognostic factor in a relative large number of patients with pNETs.
Materials and methods: Consecutive patients were retrospectively collected from a single institution between June 2006 and February 2015. The receiver operating characteristic (ROC) curve and area under the ROC curve were used to select the best cut-off values for baseline CA19-9 levels. The primary end point was overall survival. Potential factors related to abnormal elevation of CA19-9 in pNETs were also investigated.
Conference: 13th Annual ENETS conference 2016 (2016)
Presenting Author: Dr Kaizhou Jin
, Guo M
, Liu Z
, Liu C
, Cheng H
, Lu Y
, Jin K
, Zhang B
, Liu L
, Long J
, Xu J
, Ni Q
, Chen J
, Yu X
To read results and conclusion, please login ...
Further abstracts you may be interested in